Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia. Show more
Location: Toowong Tower, Toowong, QLD, 4066, Australia | Website: https://anteristech.com | Industry: Medical Instruments & Supplies | Sector: Healthcare
Market Cap
138.7M
52 Wk Range
$2.34 - $8.79
Previous Close
$3.72
Open
$3.72
Volume
120,739
Day Range
$3.60 - $3.94
Enterprise Value
89.59M
Cash
48.96M
Avg Qtr Burn
-16.8M
Insider Ownership
0.21%
Institutional Own.
64.12%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|